Serina Therapeutics Past Earnings Performance
Past criteria checks 0/6
Serina Therapeutics's earnings have been declining at an average annual rate of -687.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 2368.9% per year.
Key information
-687.1%
Earnings growth rate
-414.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 2,368.9% |
| Return on equity | n/a |
| Net Margin | -220.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Serina Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -7 | 6 | 0 |
| 31 Mar 24 | 3 | -11 | 5 | 0 |
| 31 Dec 23 | 3 | 5 | 4 | 0 |
| 30 Sep 23 | 0 | 4 | 2 | 0 |
| 30 Jun 23 | 0 | 1 | 2 | 0 |
| 31 Mar 23 | 0 | 0 | 2 | 0 |
| 31 Dec 22 | 1 | -3 | 1 | 0 |
| 31 Dec 21 | 3 | -1 | 1 | 0 |
Quality Earnings: 2BO is currently unprofitable.
Growing Profit Margin: 2BO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2BO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2BO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2BO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 2BO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.